{"id":"sultopride","rwe":[{"pmid":"38045460","year":"2023","title":"Psychotherapeutic drug-induced life-threatening arrhythmias: A retrospective analysis using the Japanese adverse drug event report database.","finding":"","journal":"Journal of arrhythmia","studyType":"Clinical Study"},{"pmid":"30000816","year":"2006","title":"Amisulpride.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"38868658","year":"2022","title":"A systematic review and network meta-analysis of antimanic drugs for the treatment of acute mania used in Japan.","finding":"","journal":"PCN reports : psychiatry and clinical neurosciences","studyType":"Clinical Study"},{"pmid":"34334499","year":"2021","title":"Inhibitory Effects of Antipsychotics on the Contractile Response to Acetylcholine in Rat Urinary Bladder Smooth Muscles.","finding":"","journal":"Biological & pharmaceutical bulletin","studyType":"Clinical Study"},{"pmid":"31506572","year":"2020","title":"Isosibiricin inhibits microglial activation by targeting the dopamine D1/D2 receptor-dependent NLRP3/caspase-1 inflammasome pathway.","finding":"","journal":"Acta pharmacologica Sinica","studyType":"Clinical Study"}],"tags":[{"label":"sultopride","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"D(2) dopamine receptor","category":"target"},{"label":"DRD2","category":"gene"},{"label":"DRD3","category":"gene"},{"label":"N05AL02","category":"atc"},{"label":"Active","category":"status"},{"label":"Antidepressive Agents","category":"pharmacology"},{"label":"Antidepressive Agents, Second-Generation","category":"pharmacology"},{"label":"Antipsychotic Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Dopamine Agents","category":"pharmacology"},{"label":"Dopamine Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"},{"label":"Tranquilizing Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"barnetil","offLabel":[],"synonyms":["sultopride HCl","sultopride hydrochloride","sultopride","barnetil","(+/-)-Sultopride"],"timeline":[],"approvals":[],"brandName":"Barnetil","ecosystem":[],"mechanism":{"target":"D(2) dopamine receptor, D(3) dopamine receptor","targets":[{"gene":"DRD2","source":"DrugCentral","target":"D(2) dopamine receptor","protein":"D(2) dopamine receptor"},{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor"}],"modality":"Small Molecule","drugClass":"sultopride","explanation":"Think of dopamine like a messenger in your brain that helps you feel happy and motivated. When Barnetil blocks the D(2) receptor, it can help reduce excessive dopamine activity that may contribute to psychiatric symptoms. This can lead to improved mood and reduced anxiety.","oneSentence":"Barnetil works by blocking the D(2) dopamine receptor, which helps regulate mood and emotional responses.","technicalDetail":"SULTOPRIDE acts as a selective antagonist at the D(2) dopamine receptor subtype, which is involved in the regulation of motor function, mood, and emotional responses. By blocking this receptor, SULTOPRIDE can modulate the activity of dopamine and its downstream signaling pathways, leading to its therapeutic effects."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2541","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=SULTOPRIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SULTOPRIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:45:36.706394","biosimilars":[],"competitors":[{"drugName":"amisulpride","drugSlug":"amisulpride","fdaApproval":"2020-02-26","patentExpiry":"Mar 10, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"sultopride","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"amisulpride","brandName":"amisulpride","genericName":"amisulpride","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07494305","phase":"PHASE2","title":"Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.","status":"RECRUITING","sponsor":"LB Pharmaceuticals Inc.","startDate":"2026-01-23","conditions":["Bipolar I Disorder"],"enrollment":320,"completionDate":"2028-02"},{"nctId":"NCT02926859","phase":"PHASE2","title":"Enhancing Recovery in Early Schizophrenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2017-04-08","conditions":["Schizophrenia"],"enrollment":180,"completionDate":"2027-12"},{"nctId":"NCT07348172","phase":"EARLY_PHASE1","title":"Characterizing Drug Liking During Drug Administration in Peri-procedural Clinical Settings","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-03-01","conditions":["Drug Liking"],"enrollment":100,"completionDate":"2028-03-31"},{"nctId":"NCT06581302","phase":"NA","title":"Magnetic Seizure Therapy for Psychotic Disorders","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-09-01","conditions":["Psychotic Disorders"],"enrollment":50,"completionDate":"2025-12-30"},{"nctId":"NCT05546359","phase":"PHASE2,PHASE3","title":"Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2024-01-18","conditions":["Nausea and Vomiting, Postoperative"],"enrollment":453,"completionDate":"2025-06-03"},{"nctId":"NCT01701258","phase":"PHASE1","title":"An Investigation of Early Life Stress and Depression","status":"COMPLETED","sponsor":"Mclean Hospital","startDate":"2013-08","conditions":["Major Depressive Disorder (MDD)","History of Childhood Sexual Abuse (CSA)"],"enrollment":153,"completionDate":"2017-05"},{"nctId":"NCT06887621","phase":"PHASE2","title":"Efficacy of Adding Oral Amisulpride to Dual Prophylaxis for Postoperative Nausea and Vomiting in Patients at High Risk for Nausea and Vomiting Undergoing Gynecological Surgery","status":"RECRUITING","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2025-04-10","conditions":["Post Operative Nausea and Vomiting (PONV)"],"enrollment":276,"completionDate":"2027-03-31"},{"nctId":"NCT04128683","phase":"EARLY_PHASE1","title":"Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2020-10-20","conditions":["Anorexia Nervosa"],"enrollment":31,"completionDate":"2025-01-01"},{"nctId":"NCT03510325","phase":"PHASE3","title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-02-12","conditions":["Schizophrenia"],"enrollment":762,"completionDate":"2023-09-27"},{"nctId":"NCT01029769","phase":"NA","title":"Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2009-12","conditions":["Schizophrenia","Schizoaffective Disorder","Schizophreniform Disorder"],"enrollment":350,"completionDate":"2015-03"},{"nctId":"NCT06585540","phase":"PHASE3","title":"A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea and Vomiting in the Bariatric Surgery Population","status":"RECRUITING","sponsor":"Benaroya Research Institute","startDate":"2024-09-13","conditions":["Post Operative Nausea and Vomiting"],"enrollment":100,"completionDate":"2026-01"},{"nctId":"NCT04876521","phase":"PHASE4","title":"Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2019-10-14","conditions":["Post-Schizophrenic Depression"],"enrollment":60,"completionDate":"2021-06-30"},{"nctId":"NCT04218981","phase":"NA","title":"Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders","status":"COMPLETED","sponsor":"Central South University","startDate":"2020-01-15","conditions":["Common Mental Disorder"],"enrollment":200,"completionDate":"2023-12-31"},{"nctId":"NCT01972711","phase":"PHASE1","title":"Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2014-03","conditions":["Schizophrenia"],"enrollment":105,"completionDate":"2015-07"},{"nctId":"NCT05956600","phase":"NA","title":"An Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Amisulpride in Treating Patients With Schizophrenia and Schizoaffective Disorder Who Have Treatment-Resistant Positive Symptoms","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2023-11","conditions":["Schizophrenia, Treatment-Resistant"],"enrollment":0,"completionDate":"2026-01"},{"nctId":"NCT04529226","phase":"PHASE2","title":"Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2020-11-26","conditions":["Psychosis","Intellectual Disability"],"enrollment":75,"completionDate":"2025-12-30"},{"nctId":"NCT05347199","phase":"PHASE1","title":"Effects of a Single Dose of Amisulpride on Functional Brain Changes","status":"COMPLETED","sponsor":"Simone Grimm","startDate":"2022-05-17","conditions":["Major Depressive Disorder"],"enrollment":127,"completionDate":"2023-09-25"},{"nctId":"NCT06066112","phase":"PHASE1","title":"Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets in Human Body","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2023-09-20","conditions":["Bioequivalence","Schizophrenia"],"enrollment":100,"completionDate":"2024-03-31"},{"nctId":"NCT06040944","phase":"","title":"Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2022-09-01","conditions":["Schizophrenia Spectrum and Other Psychotic Disorders","Periodontal Diseases"],"enrollment":64,"completionDate":"2022-11-01"},{"nctId":"NCT04674670","phase":"NA","title":"Psychobiological Mechanisms Underlying Chronic Pain","status":"COMPLETED","sponsor":"susanne becker","startDate":"2021-11-01","conditions":["Fibromyalgia","Pain, Chronic","Chronic Pain, Widespread"],"enrollment":48,"completionDate":"2023-07-31"},{"nctId":"NCT05822713","phase":"PHASE3","title":"A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV.","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical (Hainan) Co., Ltd.","startDate":"2023-04-29","conditions":["PONV"],"enrollment":516,"completionDate":"2023-12-31"},{"nctId":"NCT04954365","phase":"","title":"Post Operative Nausea and Vomiting (PONV) Rescue Outcomes After Amisulpride Treatment","status":"WITHDRAWN","sponsor":"Acacia Pharma Ltd","startDate":"2022-11-01","conditions":["Nausea and Vomiting, Postoperative"],"enrollment":0,"completionDate":"2024-12"},{"nctId":"NCT04341467","phase":"NA","title":"Amisulpride Treatment for BPSD in AD Patients","status":"UNKNOWN","sponsor":"Tianjin Anding Hospital","startDate":"2019-12-01","conditions":["BPSD","Amisulpride","Olanzapine","Dementia of the Alzheimer Type"],"enrollment":76,"completionDate":"2024-05"},{"nctId":"NCT04002258","phase":"","title":"Prolactin Change in Chinese Patients With Schizophrenia After Antipsychotics Treatment","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-06-06","conditions":["Schizophrenia","Antipyretics Toxicity","Prolactin Excess"],"enrollment":10363,"completionDate":"2022-10-25"},{"nctId":"NCT03652974","phase":"PHASE4","title":"Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2018-09-06","conditions":["Schizophrenia"],"enrollment":145,"completionDate":"2021-08-30"},{"nctId":"NCT04588129","phase":"PHASE1","title":"Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers","status":"COMPLETED","sponsor":"LB Pharmaceuticals Inc.","startDate":"2021-01-05","conditions":["Schizophrenia"],"enrollment":16,"completionDate":"2021-11-15"},{"nctId":"NCT00448630","phase":"","title":"An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-10-23","conditions":["Schizophrenia","Metabolic Syndrome X"],"enrollment":328,"completionDate":"2008-07-30"},{"nctId":"NCT01498770","phase":"","title":"An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-04-01","conditions":["Bipolar Disorder"],"enrollment":42,"completionDate":"2017-12-21"},{"nctId":"NCT04849650","phase":"PHASE1","title":"PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2021-06-03","conditions":["Renal Disease, End Stage"],"enrollment":12,"completionDate":"2021-10-30"},{"nctId":"NCT03451734","phase":"","title":"Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients","status":"COMPLETED","sponsor":"Central South University","startDate":"2018-01-23","conditions":["Schizophrenia","Metabolic Syndrome"],"enrollment":2000,"completionDate":"2021-06-30"},{"nctId":"NCT04187560","phase":"PHASE1","title":"Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults","status":"COMPLETED","sponsor":"LB Pharmaceuticals Inc.","startDate":"2020-01-22","conditions":["Schizophrenia"],"enrollment":64,"completionDate":"2020-11-09"},{"nctId":"NCT01857232","phase":"PHASE2","title":"Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2013-10","conditions":["CINV"],"enrollment":342,"completionDate":"2015-02"},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":["Schizophrenia"],"enrollment":174,"completionDate":"2020-08"},{"nctId":"NCT03863691","phase":"NA","title":"Influence of Dopaminergic Blockade on Stress Responses, Motivation and Emotional Reactivity in Humans.","status":"COMPLETED","sponsor":"Philipps University Marburg","startDate":"2019-04-15","conditions":["Healthy Participants"],"enrollment":85,"completionDate":"2020-07-15"},{"nctId":"NCT04533724","phase":"EARLY_PHASE1","title":"Study on the Gut Microbial Mechanism of Negative Symptoms of Schizophrenia","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2020-10-01","conditions":["Negative Symptom","Schizophrenia","Amisulpride","Gut Microbiomes"],"enrollment":6,"completionDate":"2022-09-30"},{"nctId":"NCT04528095","phase":"PHASE3","title":"SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant Schizophrenia","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2020-12","conditions":["Treatment-resistant Schizophrenia"],"enrollment":162,"completionDate":"2022-12"},{"nctId":"NCT04446234","phase":"PHASE4","title":"Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2021-05","conditions":["Schizophrenia"],"enrollment":350,"completionDate":"2022-12-31"},{"nctId":"NCT01446328","phase":"PHASE4","title":"Bergen Psychosis Project 2 - The Best Intro Study","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2011-10","conditions":["Schizophrenia","Psychotic Disorders"],"enrollment":151,"completionDate":"2017-12"},{"nctId":"NCT02880995","phase":"NA","title":"[18 Fluorine(F)]DOPA Determinants and Predictors of Treatment Response in Psychosis","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2017-11-01","conditions":["Schizophrenia"],"enrollment":62,"completionDate":"2019-12"},{"nctId":"NCT01991821","phase":"PHASE3","title":"European Phase III Study of APD421 in PONV","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2013-07","conditions":["PONV"],"enrollment":368,"completionDate":"2014-01"},{"nctId":"NCT01609153","phase":"PHASE4","title":"Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2012-06","conditions":["Schizophrenia","Schizoaffective Disorder"],"enrollment":328,"completionDate":"2019-04"},{"nctId":"NCT02337062","phase":"PHASE3","title":"Phase IIIb Study of APD421 in Combination as PONV Prophylaxis","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2015-02","conditions":["PONV"],"enrollment":1147,"completionDate":"2015-09"},{"nctId":"NCT01991860","phase":"PHASE3","title":"US Phase III Study of APD421 in PONV","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2013-08","conditions":["PONV"],"enrollment":364,"completionDate":"2014-01"},{"nctId":"NCT02449291","phase":"PHASE3","title":"Study of APD421 as PONV Treatment (no Prior Prophylaxis)","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2015-09","conditions":["Postoperative Nausea and Vomiting"],"enrollment":568,"completionDate":"2016-07"},{"nctId":"NCT02646566","phase":"PHASE3","title":"Study of APD421 as PONV Treatment (Prior Prophylaxis)","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2016-03","conditions":["Postoperative Nausea and Vomiting"],"enrollment":705,"completionDate":"2017-01"},{"nctId":"NCT03802838","phase":"PHASE4","title":"Clinical Evaluation of Acupuncture Treatment for Negative Symptoms of Schizophrenia","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2017-10-01","conditions":["Schizophrenia"],"enrollment":50,"completionDate":"2019-09-30"},{"nctId":"NCT02661594","phase":"PHASE1","title":"Thorough QT Study of Intravenous Amisulpride","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2013-11","conditions":["Healthy"],"enrollment":40,"completionDate":"2014-03"},{"nctId":"NCT02307396","phase":"PHASE4","title":"Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-02-01","conditions":["Schizophrenia","Schizophrenia and Disorders With Psychotic Features","Schizoaffective Disorders"],"enrollment":21,"completionDate":"2016-06-22"},{"nctId":"NCT01248195","phase":"PHASE4","title":"Optimization of Treatment and Management of Schizophrenia in Europe","status":"COMPLETED","sponsor":"Rene Kahn","startDate":"2011-05","conditions":["Schizophrenia","Schizophreniform Disorder","Schizoaffective Disorder"],"enrollment":479,"completionDate":"2016-04"},{"nctId":"NCT01253421","phase":"PHASE1","title":"The Effects of Dopamine on Reward Processing","status":"COMPLETED","sponsor":"Mclean Hospital","startDate":"2012-02","conditions":["Major Depressive Disorder (MDD)"],"enrollment":159,"completionDate":"2016-05"},{"nctId":"NCT02051387","phase":"PHASE1","title":"Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study","status":"COMPLETED","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2013-01","conditions":["Schizophrenia"],"enrollment":74,"completionDate":"2017-08"},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":["Dementia","Depression","Schizophrenia","Psychosomatic Disorders","Anxiety Disorders"],"enrollment":407,"completionDate":"2017-06-28"},{"nctId":"NCT01454453","phase":"PHASE4","title":"Optimisation of Antipsychotic Drug Use in Older People","status":"TERMINATED","sponsor":"Institute of Psychiatry, London","startDate":"2012-05","conditions":["Alzheimer's Disease","Schizophrenia"],"enrollment":64,"completionDate":"2015-07"},{"nctId":"NCT01555814","phase":"NA","title":"Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen","status":"COMPLETED","sponsor":"Birte Glenthoj","startDate":"2011-05","conditions":["Schizophrenia","Schizophreniform Disorder","Schizoaffective Disorder"],"enrollment":56,"completionDate":"2016-10"},{"nctId":"NCT01154829","phase":"NA","title":"Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS)","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2008-12","conditions":["Schizophrenia"],"enrollment":136,"completionDate":"2016-05"},{"nctId":"NCT01615185","phase":"PHASE4","title":"A Randomized, Double-blind, Comparison of the Efficacy and Safety of Amisulpride Versus Low-dose Amisulpride Plus Low-dose Sulpiride in the Treatment of Schizophrenia","status":"TERMINATED","sponsor":"Kaohsiung Kai-Suan Psychiatric Hospital","startDate":"2008-01","conditions":["Schizophrenia"],"enrollment":96,"completionDate":"2011-12"},{"nctId":"NCT01448499","phase":"NA","title":"Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients","status":"WITHDRAWN","sponsor":"Geha Mental Health Center","startDate":"2011-10","conditions":["Schizophrenia","Treatment Resistant Disorders"],"enrollment":0,"completionDate":""},{"nctId":"NCT02557984","phase":"NA","title":"Dopamine and Opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward Impulsivity","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2014-02","conditions":["Addiction"],"enrollment":121,"completionDate":"2014-04"},{"nctId":"NCT01246232","phase":"PHASE4","title":"Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2011-09","conditions":["Schizophrenia"],"enrollment":69,"completionDate":"2015-03"},{"nctId":"NCT01795183","phase":"PHASE4","title":"Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-11","conditions":["Schizophrenia"],"enrollment":316,"completionDate":"2013-12"},{"nctId":"NCT00204061","phase":"PHASE4","title":"Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2001-01","conditions":["Schizophrenia","Psychoses"],"enrollment":124,"completionDate":"2005-06"},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":["Psychosis Nos/Other"],"enrollment":104,"completionDate":"2015-11"},{"nctId":"NCT00471588","phase":"PHASE1","title":"Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08","conditions":["Obsessive-Compulsive Disorder"],"enrollment":52,"completionDate":"2007-12"},{"nctId":"NCT01323205","phase":"PHASE2","title":"Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-05","conditions":["Schizophrenia"],"enrollment":100,"completionDate":"2012-12"},{"nctId":"NCT02095938","phase":"PHASE4","title":"Association of Amisulpride Response in Schizophrenia With Brain Image","status":"UNKNOWN","sponsor":"CHA University","startDate":"2014-01","conditions":["Schizophrenia","Schizophreniform Disorder"],"enrollment":20,"completionDate":"2015-12"},{"nctId":"NCT00956189","phase":"NA","title":"Identification and Treatment Response Prediction of Antipsychotic-Related Metabolic Syndrome","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2009-11","conditions":["Metabolic Syndrome X"],"enrollment":132,"completionDate":"2012-10"},{"nctId":"NCT00534573","phase":"PHASE3","title":"Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation","status":"COMPLETED","sponsor":"Beersheva Mental Health Center","startDate":"2008-11","conditions":["Clozapine-induced Hypersalivation"],"enrollment":54,"completionDate":"2009-01"},{"nctId":"NCT00761670","phase":"PHASE4","title":"Efficacy Study on Cognitive Functions in Schizophrenic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-09","conditions":["Schizophrenia"],"enrollment":37,"completionDate":"2010-01"},{"nctId":"NCT01185418","phase":"","title":"Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer","status":"COMPLETED","sponsor":"Chonbuk National University Hospital","startDate":"2009-03","conditions":["Normal Volunteers"],"enrollment":80,"completionDate":"2009-07"},{"nctId":"NCT01160991","phase":"NA","title":"Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism","status":"COMPLETED","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2004-05","conditions":["Schizophrenia","Diabetes","Insulin Resistance"],"enrollment":10,"completionDate":"2006-10"},{"nctId":"NCT01105481","phase":"PHASE4","title":"Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2006-05","conditions":["Treatment-resistant Schizophrenia"],"enrollment":273,"completionDate":"2008-06"},{"nctId":"NCT00304616","phase":"PHASE4","title":"SWitching to Abilify Trial (SWAT)","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2004-10","conditions":["Schizophrenia"],"enrollment":500,"completionDate":"2007-10"},{"nctId":"NCT00926965","phase":"PHASE4","title":"Tardive Dyskinesia and Cognitive Function","status":"COMPLETED","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2003-01","conditions":["Tardive Dyskinesia","Neurocognitive Function"],"enrollment":80,"completionDate":"2007-12"},{"nctId":"NCT00419653","phase":"PHASE4","title":"Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy","status":"TERMINATED","sponsor":"University of Jena","startDate":"2003-01","conditions":["Schizophrenia"],"enrollment":19,"completionDate":"2007-09"},{"nctId":"NCT00436371","phase":"PHASE4","title":"Amisulpride in Schizophrenic Acute Phase Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-05","conditions":["Schizophrenia"],"enrollment":50,"completionDate":""},{"nctId":"NCT00245674","phase":"PHASE4","title":"SOLIACS: Solian Solution in the Acute Setting","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-06","conditions":["Schizophrenia"],"enrollment":300,"completionDate":""},{"nctId":"NCT00331981","phase":"PHASE4","title":"Amisulpride in Schizophrenic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-02","conditions":["Schizophrenia"],"enrollment":138,"completionDate":""},{"nctId":"NCT00126009","phase":"PHASE2","title":"SOLMANIA - Comparison of Valproate-Amisulpride and Valproate-Haloperidol in Bipolar I Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-05","conditions":["Bipolar Disorder"],"enrollment":120,"completionDate":""},{"nctId":"NCT00628290","phase":"PHASE2","title":"Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2002-10","conditions":["Schizophrenia"],"enrollment":42,"completionDate":"2008-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"005343","UNII":"AA0G3TW31W","CHEBI":"CHEBI:9356","INN_ID":"3113","RXNORM":"236185","UMLSCUI":"C0075630","ChEMBL_ID":"CHEMBL277945","KEGG_DRUG":"D02208","DRUGBANK_ID":"DB13273","PUBCHEM_CID":"5357","SNOMEDCT_US":"717107003","SECONDARY_CAS_RN":"23694-17-9","MESH_DESCRIPTOR_UI":"D000077582"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":131,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N05AL02","allCodes":["N05AL02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2023 Dec","pmid":"38045460","title":"Psychotherapeutic drug-induced life-threatening arrhythmias: A retrospective analysis using the Japanese adverse drug event report database.","journal":"Journal of arrhythmia"},{"date":"2006","pmid":"30000816","title":"Amisulpride.","journal":""},{"date":"2022 Dec","pmid":"38868658","title":"A systematic review and network meta-analysis of antimanic drugs for the treatment of acute mania used in Japan.","journal":"PCN reports : psychiatry and clinical neurosciences"},{"date":"2021","pmid":"34334499","title":"Inhibitory Effects of Antipsychotics on the Contractile Response to Acetylcholine in Rat Urinary Bladder Smooth Muscles.","journal":"Biological & pharmaceutical bulletin"},{"date":"2020 Feb","pmid":"31506572","title":"Isosibiricin inhibits microglial activation by targeting the dopamine D1/D2 receptor-dependent NLRP3/caspase-1 inflammasome pathway.","journal":"Acta pharmacologica Sinica"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Barnetil is a small molecule with the synonyms SULTOPRIDA, SULTOPRIDE, and SULTOPRIDE. It has been studied in clinical trials for various conditions, including Major Depressive Disorder, Post Operative Nausea and Vomiting, Anorexia Nervosa, Clozapine-induced Hypersalivation, and Schizophrenia, with amisulpride being one of the interventions used.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}